177 related articles for article (PubMed ID: 31842288)
1. 5-Fluorouracil as a Tumor-Treating Field-Sensitizer in Colon Cancer Therapy.
Lee YJ; Cho JM; Sai S; Oh JY; Park JA; Oh SJ; Park M; Kwon J; Shin US; Beak JH; Lim SH; Song JY; Hwang SG; Kim EH
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31842288
[TBL] [Abstract][Full Text] [Related]
2. Tumor-treating fields in combination with sorafenib curtails the growth of colorectal carcinoma by inactivating AKT/STAT3 signaling.
Kim EH; Lee WS; Oh HK
Transl Cancer Res; 2022 Aug; 11(8):2553-2561. PubMed ID: 36093532
[TBL] [Abstract][Full Text] [Related]
3. Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice.
Zhang P; Lai ZL; Chen HF; Zhang M; Wang A; Jia T; Sun WQ; Zhu XM; Chen XF; Zhao Z; Zhang J
J Exp Clin Cancer Res; 2017 Dec; 36(1):190. PubMed ID: 29273065
[TBL] [Abstract][Full Text] [Related]
4. The long non-coding RNA HOTAIRM1 suppresses cell progression via sponging endogenous miR-17-5p/ B-cell translocation gene 3 (BTG3) axis in 5-fluorouracil resistant colorectal cancer cells.
Ren T; Hou J; Liu C; Shan F; Xiong X; Qin A; Chen J; Ren W
Biomed Pharmacother; 2019 Sep; 117():109171. PubMed ID: 31261026
[TBL] [Abstract][Full Text] [Related]
5. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
Voloshin T; Kaynan N; Davidi S; Porat Y; Shteingauz A; Schneiderman RS; Zeevi E; Munster M; Blat R; Tempel Brami C; Cahal S; Itzhaki A; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
Cancer Immunol Immunother; 2020 Jul; 69(7):1191-1204. PubMed ID: 32144446
[TBL] [Abstract][Full Text] [Related]
6. Demethylzeylasteral Exerts Antitumor Effects
Liu G; Lai D; Jiang Y; Yang H; Zhao H; Zhang Y; Liu D; Pang Y
Anticancer Agents Med Chem; 2022; 22(5):851-863. PubMed ID: 34102996
[TBL] [Abstract][Full Text] [Related]
7. Triacanthine enhances the sensitivity of colorectal cancer cells to 5-fluorouracil by regulating RRM2.
Liu YH; Shen MM; Wu YC; Luo KZ; Zhang JK; Wang Z; Chen ZY; Li J; Wu SY; Lin NM; Zhang C; Li YL
Phytomedicine; 2024 Apr; 126():155204. PubMed ID: 38342015
[TBL] [Abstract][Full Text] [Related]
8. The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy.
Tanzhu G; Chen L; Xiao G; Shi W; Peng H; Chen D; Zhou R
Cell Death Discov; 2022 Oct; 8(1):416. PubMed ID: 36220835
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of tumor‑treating fields to reduce the proliferation and migration of liposarcoma cell lines.
Lee WS; Jang Y; Cho A; Kim YB; Bu YH; Yang S; Kim EH
Exp Ther Med; 2023 Aug; 26(2):363. PubMed ID: 37408858
[TBL] [Abstract][Full Text] [Related]
10. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
[TBL] [Abstract][Full Text] [Related]
11. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo.
Giladi M; Weinberg U; Schneiderman RS; Porat Y; Munster M; Voloshin T; Blatt R; Cahal S; Itzhaki A; Onn A; Kirson ED; Palti Y
Semin Oncol; 2014 Oct; 41 Suppl 6():S35-41. PubMed ID: 25213867
[TBL] [Abstract][Full Text] [Related]
12. Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells.
Li X; Ma Y; Wu J; Ni M; Chen A; Zhou Y; Dai W; Chen Z; Jiang R; Ling Y; Yao Q; Chen W
Drug Resist Updat; 2023 Mar; 67():100930. PubMed ID: 36736043
[TBL] [Abstract][Full Text] [Related]
13. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
14. Tumor-treating fields in combination with sorafenib restrain the proliferation of liver cancer
Jang Y; Lee WS; Sai S; Kim JY; Kim JK; Kim EH
Oncol Lett; 2022 Oct; 24(4):338. PubMed ID: 36039063
[TBL] [Abstract][Full Text] [Related]
15. Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells.
Ding W; Wang JX; Wu JZ; Liu AC; Jiang LL; Zhang HC; Meng Y; Liu BY; Peng GJ; Lou EZ; Mao Q; Zhou H; Tang DL; Chen X; Liu JB; Shi XP
Acta Pharmacol Sin; 2023 Dec; 44(12):2537-2548. PubMed ID: 37528233
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of Doxorubicin with TTFields and radiation: newer approaches to combat lung cancer.
Lee WS; Kim EH
Am J Cancer Res; 2022; 12(6):2673-2685. PubMed ID: 35812042
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway.
Hua R; Zhang Y; Yan X; Tang D; Li X; Ni Q; Wang D; Zhu J
Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1547-1557. PubMed ID: 34596215
[TBL] [Abstract][Full Text] [Related]
18. Prodigiosin impairs autophagosome-lysosome fusion that sensitizes colorectal cancer cells to 5-fluorouracil-induced cell death.
Zhao C; Qiu S; He J; Peng Y; Xu H; Feng Z; Huang H; Du Y; Zhou Y; Nie Y
Cancer Lett; 2020 Jul; 481():15-23. PubMed ID: 32184145
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer.
Zhu Y; Li K; Zhang J; Wang L; Sheng L; Yan L
Cancer Manag Res; 2020; 12():11271-11283. PubMed ID: 33177877
[TBL] [Abstract][Full Text] [Related]
20. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma
Davidi S; Jacobovitch S; Shteingauz A; Martinez-Conde A; Braten O; Tempel-Brami C; Zeevi E; Frechtel-Gerzi R; Ene H; Dor-On E; Voloshin T; Tzchori I; Haber A; Giladi M; Kinzel A; Weinberg U; Palti Y
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
